Adlai Nortye Group Ltd.
ANL Nasdaq Pharmaceutical Preparations Financials FY2021โFY2025
Last close ยท Oct 23, 2026
$10.58
0.0%What Adlai Nortye Group Ltd. does
No business description yet.
- Legal name
- Adlai Nortye Group Ltd.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F ยท Apr 10, 2026
- Accession ยท CIK
- 0001213900-26-042520
0001944552
Revenue and margins
Adlai Nortye Group Ltd. had $5.0M of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was โ$33.6M in fiscal 2025, โ672.8% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Adlai Nortye Group Ltd. returned โ to shareholders in fiscal 2025. The diluted share count rose 0.2%.
Balance sheet
Cash, debt and the ratios that show how comfortably Adlai Nortye Group Ltd. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $64.1M | $42.8M | $91.5M | $60.9M | $8.1M |
| Debt incl. finance leases | $10.5M | $4.3M | $30.4M | $26.3M | $24.6M |
| Debt / equity | โ | โ | 0.4x | 1.0x | โ |
| Interest coverage | โ6.5x | โ155.4x | โ91.7x | โ27.2x | โ23.3x |
| Current ratio | โ | 0.2x | 2.0x | 1.4x | 0.6x |
| Quick ratio | โ | 0.2x | 2.0x | 1.4x | 0.6x |
| Total assets | โ | $72.6M | $130M | $71.3M | $34.4M |
| Total liabilities | โ | $314M | $55.1M | $45.8M | $42.8M |
| Shareholders' equity | โ$185M | โ$241M | $75.0M | $25.5M | โ$8.3M |
| Net debt (โ = net cash) | โ$53.7M | โ$38.5M | โ$61.1M | โ$34.6M | $16.5M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 4 | 2 / 7 | 2 / 7 | 1 / 7 |
| Accruals ratio | โ | โ21.4% | โ51.9% | โ0.0% | โ3.9% |
| Altman Z'' | โ | โ41.34 | 0.39 | โ22.32 | โ53.99 |
5 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $45.7M | โ | $5.0M | โ | $5.0M |
| Research and development | $42.1M | $54.5M | $58.2M | $44.9M | $32.8M |
| Operating income | โ$8.6M | โ$67.3M | โ$72.6M | โ$52.9M | โ$35.7M |
| Interest expense | $1.3M | $0.4M | $0.8M | $1.9M | $1.5M |
| Pretax income | โ$56.7M | โ$58.8M | โ$109M | โ$51.9M | โ$35.5M |
| Income tax | โ | โ | $0.6M | โ | โ |
| Net income | โ$56.7M | โ$58.8M | โ$109M | โ$51.9M | โ$35.5M |
| Net income to common | โ$56.7M | โ$58.8M | โ$109M | โ$51.9M | โ$35.5M |
| Diluted EPS | โ$6.69 | โ$6.93 | โ$7.56 | โ$1.62 | โ$1.11 |
| Diluted shares | 0.01B | 0.01B | 0.01B | 0.03B | 0.03B |
| Cash flow | |||||
| Cash from operations | โ$3.0M | โ$43.2M | โ$56.7M | โ$51.8M | โ$33.5M |
| Capital expenditure | $1.0M | $1.2M | $0.2M | $0.2M | $0.2M |
| Free cash flow | โ$4.1M | โ$44.5M | โ$56.9M | โ$52.0M | โ$33.6M |
| Depreciation and amortization | โ | $0.6M | $0.5M | $0.5M | $0.5M |
| Stock-based compensation | $3.4M | $6.1M | $4.3M | $2.5M | $1.5M |
| Balance sheet | |||||
| Cash and short-term investments | $64.1M | $42.8M | $91.5M | $60.9M | $8.1M |
| Total debt | $10.5M | $4.3M | $30.4M | $26.3M | $24.6M |
| Current assets | โ | $66.3M | $101M | $64.1M | $26.9M |
| Current liabilities | โ | $313M | $49.7M | $45.4M | $41.6M |
| Property and equipment, net | $3.7M | $3.7M | $2.6M | $1.7M | $1.2M |
| Intangible assets | โ | $0.1M | $0.1M | $0.0M | $0.0M |
| Total assets | โ | $72.6M | $130M | $71.3M | $34.4M |
| Total liabilities | โ | $314M | $55.1M | $45.8M | $42.8M |
| Shareholders' equity | โ$185M | โ$241M | $75.0M | $25.5M | โ$8.3M |
| Margins | |||||
| Operating margin | โ18.9% | โ | โ1,451.0% | โ | โ714.0% |
| EBITDA margin | โ | โ | โ1,441.7% | โ | โ704.4% |
| Net margin | โ124.0% | โ | โ2,184.6% | โ | โ710.6% |
| FCF margin | โ8.9% | โ | โ1,137.0% | โ | โ672.8% |
| Returns | |||||
| Return on capital | โ | โ | โ412.0% | โ | โ343.8% |
| Return on capital employed | โ | 28.0% | โ90.1% | โ204.3% | 496.2% |
| Return on equity | โ | โ | โ | โ103.2% | โ414.0% |
| Return on assets | โ | โ81.0% | โ107.7% | โ51.5% | โ67.2% |
| Return on tangible equity | โ | โ | โ145.7% | โ203.8% | โ |
| Growth | |||||
| Share count change | โ | 0.0% | 70.4% | 121.0% | 0.2% |
| Financial health | |||||
| Debt / equity | โ | โ | 0.4x | 1.0x | โ |
| Interest coverage | โ6.5x | โ155.4x | โ91.7x | โ27.2x | โ23.3x |
| Current ratio | โ | 0.2x | 2.0x | 1.4x | 0.6x |
| Quick ratio | โ | 0.2x | 2.0x | 1.4x | 0.6x |
| Capital allocation | |||||
| Capex / revenue | 2.2% | โ | 4.0% | โ | 3.7% |
| Stock comp / revenue | 7.4% | โ | 86.6% | โ | 30.6% |
| Quality scores | |||||
| Piotroski F-score | โ | โ | 2.0 | 2.0 | 1.0 |
| Altman Z'' | โ | โ41.3 | 0.4 | โ22.3 | โ54.0 |
| Accruals ratio | โ | โ21.4% | โ51.9% | โ0.0% | โ3.9% |
Source: SEC EDGAR XBRL filings (CIK 0001944552). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Per-share figures are per US-listed share (1 ADS = 3 ordinary shares). For information only โ not investment advice. Check the original filings before relying on any figure.